Key result
Hypertrophic cardiomyopathy is a common genetic disease that can lead to sudden cardiac death, for which high-risk patients benefit from implantable cardioverter-defibrillators.
Highlights the risk of sudden cardiac death in hypertrophic cardiomyopathy, the benefit of ICDs in high-risk patients, and the importance of preparticipation screening in athletes.
Supports ICD use in high-risk HCM; leaves open optimal risk stratification and screening protocols.
Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease that affects the left ventricle. HCM can appear at any age, with the majority of the patients remaining clinically stable. When patients complain of symptoms, these include: dyspnea, dizziness, syncope and angina. HCM can lead to sudden cardiac death (SCD), mainly due to ventricular tachyarrhythmia or ventricular tachycardia. High-risk patients benefit from implantable cardioverter-defibrillators. Left ventricular outflow tract obstruction is not a rare feature in HCM, especially in symptomatic patients, and procedures that abolish that obstruction provide positive and consistent results that can improve long-term survival. HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. The structure of these programs is a matter of large debate. Worldwide registries are necessary to identify the full extent of HCM-related SCD.
No takes yet. Share an insight, caveat, or question.
Konstantinos Stroumpoulis (2010) conducted a review in Hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy is a common genetic disease that can lead to sudden cardiac death, for which high-risk patients benefit from implantable cardioverter-defibrillators.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: